Rx Cost-Effectiveness Data Requirement Would Raise Prices – AstraZeneca
Executive Summary
Requiring pharmaceutical companies to collect cost-effectiveness data would lead to higher Rx pricing, AstraZeneca CEO Tom McKillop said during the company's annual business review Nov. 7
You may also be interested in...
Medicare Rx Positioning For 2003: Merck Prepares Investors For Benefit
Merck is telling investors to expect a "meaningful" Medicare prescription drug benefit in the 108th Congress
Medicare Rx Positioning For 2003: Merck Prepares Investors For Benefit
Merck is telling investors to expect a "meaningful" Medicare prescription drug benefit in the 108th Congress
FDA, CMS Coordination On Coverage Decisions May Improve Under McClellan
FDA and the Centers for Medicare & Medicaid Services are likely to have a closer relationship under incoming Commissioner McClellan